SEC Form 4 · accession 0001209191-15-001703
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth E Reed
Officer — VP, General Counsel
Period of report
Jan 1, 2015
Accepted (ET)
Jan 5, 2015 · 8:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 169 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2,F3 | $19.53 | Jan 1, 2015 | A | 72,000 | A | Jan 1, 2016 | Dec 31, 2024 | Common Stock | 72,000 | 142,500 | D |
Explanation of responses
- F1The amount includes shares purchased under Celladon Corporation's employee stock purchase plan prior to the reported transaction.
- F2Grant of stock option under the Issuer's 2013 Equity Incentive Plan.
- F325% of the shares subject to the option vest and become exercisable on the one year anniversary of January 1, 2015 (the "Vesting Commencement Date"), and 1/48th of the shares vest in equal monthly installments thereafter, over the remaining three years.